Newsletter · 2026-07-17 · Ashutosh Agarwal

UnitedHealth Blowout and Cheaper GLP-1 Copies Reframe the Healthcare Trade - Healthcare Podcast Weekly Digest - Week of July 17, 2026

Healthcare podcast digest for the week of July 11 to 17, 2026. UnitedHealth's blowout quarter single-handedly lifted the Dow and reopened the question of whether a long-unloved sector is worth a second look, against cheaper GLP-1 copies abroad, a wave of mega-mergers, and a renewed fight over drug-pricing middlemen.

Healthcare Podcast Weekly Digest

Week of July 17, 2026: UnitedHealth Blowout and Cheaper GLP-1 Copies Reframe the Healthcare Trade

What portfolio managers, analysts, drug-industry executives and doctors were actually saying on the podcasts this week, plus the news and policy moves behind it.

1. The Big Picture This Week

Two words carried the week in healthcare: UnitedHealth.

For most of the past year, the biggest U.S. health insurer had been the sector's problem child. Its stock had fallen from roughly $630 to under $300 after a string of missteps in 2025. Then, on Wednesday (July 16), the company reported a quarter so strong it single-handedly pushed the Dow into positive territory. On CNBC's Morning Call (July 16), the moment was described live: "UNH shares up 5%. That's about 20 bucks and change per share... we're talking about 140 points roughly added to the Dow just on the back of UNH earnings." Jim Cramer, on Squawk on the Street (July 16), summed up the mood bluntly: the insurers are "in a medical advantage nirvana right now," while hospital chains like HCA "got stiffed."

That single earnings report crystallized a bigger theme running through the week's podcasts and market chatter: after badly lagging the broad market, healthcare is starting to look interesting again to the investors who had written it off. On Morningstar's Investing Insights (July 10), an analyst said flatly, "we're still overweight healthcare... Fundamentals are holding up quite well, and performance has really lagged the broad U.S. market. So we think that gap could narrow." The catch, noted on Bloomberg Surveillance (July 15): with 10 of 11 S&P sectors expected to grow earnings this quarter, healthcare was "the only one it's not joining the party", though WSJ's Take On the Week (July 12) pointed out that the projected earnings decline is skewed by one-off accounting charges at Gilead tied to a deal, not by the sector's core health falling apart.

Underneath the headlines, three structural forces dominated: the rollout of Medicare's new GLP-1 "Bridge" program and the changing economics of obesity drugs; a wave of very large pharma and hospital mergers; and a renewed fight over drug-pricing middlemen (the "PBMs"). Here's what people were actually saying.

2. Key People This Week

3. Hot Topics

UnitedHealth's Blowout, and Why It Matters Beyond One Stock

The numbers were the story. UnitedHealth reported adjusted earnings of $6.38 a share against expectations of $4.92, its biggest beat since the second quarter of 2020, on revenue of $112.03B (vs. ~$110.86B expected). It then raised its full-year 2026 profit forecast to $19.50–$20.00 a share, up from "more than $18.25" (Wall Street had penciled in about $18.48), on full-year revenue guidance of roughly $439 billion (as laid out on Schwab Network, July 16).

What actually drove it, per the CFO's on-air interview on Squawk on the Street (July 16): the company raised prices (premiums), adjusted plan benefits to match rising medical costs, cut unprofitable contracts, and is spending about $1.5 billion on AI to streamline back-office work like prior authorizations and fraud detection. Crucially, its "medical benefit ratio", the share of premium dollars paid out as medical claims and the single most-watched number for an insurer, "improved more than analysts had expected." The CFO stressed AI would not be used to approve or deny individual claims.

The read-through, as Cramer framed it on Squawk on the Street (July 16): insurers and hospitals are now moving in opposite directions. "UNH, they got the big win... HCA gets stiffed." His explanation for the hospital pain was specific and non-obvious: it wasn't fewer procedures, it was testing volumes and uninsured patients: "It was LabCorp. It was Quest. It was people who went in to the hospital without insurance... and then didn't pay." His takeaway on the diagnostics names: "Don't buy LabCorp."

Wall Street had been rushing to get more positive even before the print. In the days leading up to earnings, price-target hikes piled up: Wells Fargo to $485 (from $397), Truist to $480, KeyBanc and Piper Sandler both to $475, RBC to $463, and TD Cowen to $430 (from $337), all per The Fly. The single biggest change of heart came the morning of the report, when Baird upgraded UNH to Neutral from Underperform and more than doubled its price target to $453 from $287, citing management's aggressive cost actions, though Baird stayed cautious on the long-term earnings power of the Optum division. As Stephanie Link put it on Morning Call (July 16): "It's still a value. It's trading at 17 times earnings and about 18 times EBITDA. And this historically has traded in the 20s... I might even buy some more."

One important nuance for the rest of the sector: UnitedHealth's comment about a higher cost trend in its employer-plan business actually dinged rival Elevance Health, which fell about 8.5% even after beating estimates, a reminder that not every insurer is in "nirvana."

GLP-1 Obesity Drugs: Cheaper Copies Abroad, a Bigger Market Everywhere

The most substantive investment discussion of the week came from Morgan Stanley's pharma team on Thoughts on the Market (July 13), walking through what happens as the first low-cost copies ("generics") of semaglutide, the molecule behind Ozempic and Wegovy, hit the market overseas.

The early data from India is striking. The patent expired there in March 2026, and "13 companies have launched 26 generics." Because India was barely using these drugs before, cheap prices are pulling in huge new demand: "the volume in April 2026 were already six times higher than the volume in February," with generics grabbing "80% of semaglutide volume in April." Counterintuitively, the analysts expect India's GLP-1 market to grow in dollar terms even as prices fall, "from $125 million in [20]25 to more than $1 billion by 2030." Copies are also launching in Canada and Brazil. The key dates for U.S. and European investors: the semaglutide patent doesn't expire in Europe until 2031 and the U.S. until 2032, so this is a preview, not an imminent threat.

The bull case for staying invested in the branded leaders rests on tirzepatide (Eli Lilly's Mounjaro/Zepbound), which hits two hormone pathways instead of one and delivers "not only better efficacy, but also improved tolerability." That's letting Lilly hold onto premium-paying customers even where cheap copies exist, tirzepatide already has "about 60%" U.S. market share. And a new front is opening: pills. Oral versions are "expanding the market," because "the majority of people that are taking the oral versions... are new users."

But the real-world picture is messier than the trial data, and several podcasts dug into it:

• On On The Pen (July 14), a real-world analysis of more than 60,000 commercially insured diabetes patients found "about 40% of patients... discontinued [in] the first year," rising to "around 60%" by two years. The more interesting, and underreported, finding: 41.5% restarted within a year, and 58% within two years. The host's point: those gaps usually reflect insurance and access problems, "not... efficacy failure." As she put it, "instead of asking why so many patients stopped GLP-1 therapy, maybe we should be asking why so many of them eventually came back."
• On Consumerpedia (July 16), Dr. David Cummings laid out the efficacy gap plainly: semaglutide delivers roughly 15% weight loss, tirzepatide roughly 22%, but the drugs "must be taken indefinitely" with "75% weight regain upon discontinuation."

Medtech: Quality Names on the Bargain Rack, or Value Traps?

A recurring theme was that money leaving healthcare to chase AI has left high-quality medical-device makers deeply out of favor. On Stock Club (July 16), the hosts ran through the damage year-to-date: Intuitive Surgical down 27%, Boston Scientific down 54% (about 60% off its highs), Medtronic down 13%, ResMed down 19%, Dexcom down more than 50% from its peak. The argument for buying: these are businesses with "massive regulatory and infrastructure moats", since FDA approval and physical, implanted products are barriers AI can't easily cross, so "AI will enhance rather than disrupt" them. Their picks: Intuitive Surgical, Stryker, and Boston Scientific. The caveat they flagged: a couple of these (Dexcom in diabetes, ResMed in sleep apnea) sit "at the wrong end of the GLP-1 trend," since better obesity treatment could shrink their end-markets.

4. Key Debates (Bull vs. Bear)

Debate 1: Has the FDA lowered the bar too far on rare-disease drugs?

• Bull: A more permissive FDA is a gift to small biotech. On Biotech Hangout (July 10), analysts noted that Agios's sickle-cell drug (P-VAT) missed its main goal yet still won priority review, and that the agency signaled an outcome study won't even be required. Eric Greenwald said his estimated odds of approval for several once-left-for-dead programs jumped "from 10 or 20 percent... to 70 or 80 percent." "The FDA is open for business."
• Bear: The same panel worried aloud about "swinging... too far to the right." Josh reminded everyone that "we're making decisions on behalf of patients," and that some recent muscular-dystrophy drugs arguably "offer more harm than benefit." Approving expensive drugs whose benefit "has not been proven in clinical ways" carries "cost to society."

Debate 2: Does the AI mania help or hurt biotech?

• Bull: If the AI trade cracks, that money has to go somewhere. On BioCentury This Week (July 14), Stephen Hansen relayed an investor's math: post-IPO, SpaceX alone was worth about 6% of U.S. GDP, and the seven biggest AI spenders together topped $17 trillion, roughly 53% of GDP. When capital eventually rotates out, "maybe it starts looking at places like biotech."
• Bear: Or it drags everything down. That same concentration means a burst AI bubble "could drag everything else down, just given the massive size of these companies."

Debate 3: Is oral semaglutide's Alzheimer's flop a warning on GLP-1 "halo" claims?

• Bear: On Fat Science (July 13), Dr. Cooper detailed Novo Nordisk's Evoke and Evoke Plus trials (results released November 2025, ~3,800 early-Alzheimer's patients on oral semaglutide over two years): the drug "improved some of the Alzheimer's disease biomarkers" but "did not change that clinical course of the disease." A caution against assuming GLP-1s fix everything.
• Counterpoint: The same episode highlighted the US POINTER lifestyle study (~2,100 at-risk adults, published 2025), where structured exercise, Mediterranean-style diet, cognitive challenge and social engagement produced "significantly more improvement" in cognition, a reminder that the cheapest intervention still works.

Debate 4: Insurers vs. hospitals, who wins the cost cycle?

The week's clearest divide. Insurers (UNH) are getting a handle on medical costs and repricing plans; hospitals (HCA) are being squeezed by uninsured patients and soft testing volumes. As Cramer put it on Squawk on the Street (July 16): "UNH, they win. HCA gets stiffed."

5. Emerging Themes

Biotech's asymmetric-bet playbook is back. On the Value Hive Podcast (July 10), a biotech investor walked through a string of multibaggers built on buying after the data lands, not before: Eurogen ran "from $3 to $38" on an approval the market had priced as a rejection; Abivax is "up 2,000%" after strong ulcerative-colitis data when the stock had "one week of runway left"; Nectar Therapeutics went "from $8... as high as $109 in one year" after a legal reversal. His broader observation on how frothy the space is: Revolution Medicine carries a "$40 billion" market value with "zero revenue", "I don't know if any other sector has that."

"Delinking" is coming for drug middlemen. The biggest structural announcement was OptumRx's move (on Prescription for Better Access, July 15) to a flat per-member fee that "delinks" its pay from the price of drugs, plus passing through "100% of rebates." President Kathryn Carey expects 30–60% of its 5,000 clients (covering 61 million people) to adopt it by 2027–2029, essentially making the big commercial market "behave more like the government market." It's a direct response to years of political heat on PBMs.

AI as a cost lever, not just a product. UnitedHealth's $1.5 billion AI budget is explicitly aimed at cutting its own operating costs (prior authorizations, fraud detection). And on Becker's Healthcare Podcast (July 15), Laura Dyrda noted hospital executives are shifting from asking whether to buy AI to demanding "the return on AI", a maturing, ROI-focused phase.

Psychedelics inch toward the mainstream. On BioSpace (July 15), Compass Pathways reported that in a second late-stage trial, "almost 40% of patients with treatment-resistant depression" saw a clinically meaningful improvement after six weeks; Jefferies is "75% to 85% confident" of approval, with a possible launch in the first half of 2027. One psychiatrist went so far as to say the drug class "has the potential to... wipe out the SSRIs", pointed timing given RFK Jr.'s stated push to get Americans off those older antidepressants.

6. Deals & M&A Tracker

Biotech M&A is doing the heavy lifting for the whole sector. Per BioCentury This Week (July 14): 33 deals of $1 billion or more closed in the first half of 2026, on pace to blow past the 39 done in all of 2025, returning about $22.8 billion to specialist investors who will plow it back into biotech.

On hospitals specifically (Becker's Healthcare Podcast, July 15): 18 transactions in Q2 2026, one of the busiest second quarters since 2019, with six mega-mergers already this year (each involving a smaller partner with $1B+ revenue), more than all of 2025. Total transacted revenue was $7.7 billion, a rebound from last year's low but still below Q2 2024 ($10.8B) and Q2 2023 ($13.3B). The tone has shifted from survival deals to proactive, strategic ones, ahead of Medicaid changes landing in 2027.

7. Regulatory Watch

• Medicare GLP-1 "Bridge" program launched July 1, 2026 and runs through Dec 31, 2027. Eligible Medicare enrollees can get select obesity drugs for a flat $50/month copay, with Medicare reported to have secured a $245 net price per 30-day supply from Lilly and Novo; the formulary covers Wegovy, Zepbound KwikPens, and Lilly's new oral pill Foundayo (orforglipron). Morgan Stanley's team on Thoughts on the Market (July 13) called it a growth driver that could "broaden access to about an additional 18 million people," while sector research puts the number of newly eligible beneficiaries under comorbidity tiers at roughly 3.6 million, the exact reach will depend on who qualifies. Importantly, big insurers are largely insulated near-term because the program runs through a central CMS system rather than regular Part D plans.
• IRA drug-price negotiations are now live. The first 10 negotiated drugs (Eliquis, Xarelto, Enbrel, Januvia, Jardiance) took effect Jan 1, 2026, estimated to save Medicare ~$6 billion and cut beneficiary out-of-pocket costs ~$1.5 billion this year, with statutory discounts of 38%–60%; the Part D out-of-pocket cap rose to $2,100 for 2026.
• FDA approvals this week: Eli Lilly won traditional FDA approval for Retevmo (selpercatinib) in RET fusion-positive solid tumors (July 14). And in Alzheimer's, Biogen and Eisai secured a surprise early approval for an at-home, under-the-skin (subcutaneous) starter version of Leqembi (BioSpace, July 15), ahead of its Aug 24 decision date. That lets Leqembi be given entirely at home, a real differentiator versus Lilly's infusion-only Kisunla, which currently holds roughly 80% of the early-treatment market.
• The Ionis/AstraZeneca shock. On BioCentury This Week (July 14), Lauren Martz detailed how a failed late-stage trial of their heart-disease drug (in ATTR cardiomyopathy) erased "over $3 billion in market cap for Ionis," with AstraZeneca also falling. The suspected culprits: over 80% of trial patients were already on a competing stabilizer drug (versus ~50% in a rival Alnylam trial), raising the bar. It reignited a long-running debate about whether one drug technology (siRNA) is simply better than another (antisense): "every time the siRNA comes out on top."
• Peptides on the docket. An FDA advisory committee meets July 23–24 to weigh whether popular peptides like BPC-157 and TB-500 can be made by compounding pharmacies (Health:Further, July 11; Hims House, July 15). One industry insider on Hims House put BPC-157's odds of a favorable vote at "75-80%."
• The PBM/generics fight is heating up. On Relentless Health Value (July 15), the host argued PBMs "extract $41 out of every $100 spent on generic drugs that cost on average like 47 cents to manufacture," and that four out of five generic prescriptions in the deductible phase are cheaper if you pay cash and skip insurance entirely. She also flagged that generic-drug adoption has slowed from "one month" to "six months on average" as PBMs tighten formulary control, a live target for policymakers.

8. The Week Ahead

FDA decision dates and data (the calendar is dense):

• July 17 (today): Celcuity (CELC), decision on its breast-cancer drug gedatolisib.
• July 18: Belite Bio (BLTE), Phase 3 DRAGON trial data for Stargardt disease at the ASRS retina meeting.
• July 23: Sanofi (SNY), decision on an under-the-skin version of its myeloma drug Sarclisa.
• July 23–24: FDA advisory committee vote on compounding eligibility for peptides (BPC-157, TB-500).
• July 24: Otsuka, decision on centanafadine for ADHD.
• July 26: MannKind (MNKD), decision on its FUROSCIX ReadyFlow autoinjector for fluid overload.
• July 29: Outlook Therapeutics (OTLK), decision on LYTENAVA in wet AMD.
• July 30: Viatris (VTRS), decision on a low-dose weekly contraceptive patch.

Earnings and data to watch: With UnitedHealth having set the tone, attention turns to the rest of healthcare's Q2 reporting season, and to Eli Lilly's upcoming print, where analysts (per multiple The Fly notes) are looking for strong U.S. Zepbound/Mounjaro scripts but watching for a slower-than-hoped launch of the new oral pill Foundayo (orforglipron). Lilly's price-target hikes have been relentless into the quarter, topped by Citi at $1,600. Also on the radar: Lilly's Alzheimer's data (Kisunla) presented at the AAIC conference in London this week, and continued fallout in the diagnostics names (LabCorp, Quest) flagged by Cramer as collateral damage from the hospital squeeze.

The overarching question: whether UnitedHealth's turnaround marks the start of a broader rotation back into a long-unloved sector, the "gap could narrow" thesis, or a one-company story in a group still facing Medicaid cuts, ACA premium spikes (insurers are proposing a median 14% increase for 2027, per Health:Further, July 11), and drug-pricing pressure on every side.